Page last updated: 2024-11-05

berbamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Berbamine is an alkaloid found in various plants, including Berberis species. It exhibits a range of pharmacological activities, including anti-inflammatory, antioxidant, and anticancer properties. Its complex structure presents a challenge for synthetic production. Studies focus on elucidating its mechanisms of action and potential therapeutic applications, particularly in the treatment of inflammatory disorders and cancer.'

Cross-References

ID SourceID
PubMed CID275182
CHEMBL ID504323
CHEBI ID3063
SCHEMBL ID19039
MeSH IDM0090214
PubMed CID10170
CHEMBL ID1198334
CHEBI ID182116
SCHEMBL ID19041
MeSH IDM0090214

Synonyms (65)

Synonym
nsc-121842
berbaman-12-ol,6',7-trimethoxy-2,2'-dimethyl-
berbenine
wln: t-t66 cnt&j c1 ho1 io- jt66 cnt&j c1 ho1 io1 b1r dq cor d1- b-18-j
NCI60_003398
nsc-369310
berbamine hydrochloride
einecs 207-523-5
ccris 6538
nsc 121842
brn 0078902
d-berbamine
(+)-berbamine
NCGC00017375-01
tnp00325
berbaman-12-ol, 6,6',7-trimethoxy-2,2'-dimethyl-
C09357
NCGC00142548-01
bdbm50241654
16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolin-12-ol, 3,4,4a,5,16a,17,18,19-octahydro-21,22,26-trimethoxy-4,17-dimethyl-, (4as-(4ar*,16as*))-
16h-1,24:6,9-dietheno-11,15-metheno-2h-pyrido(2',3':17,18)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolin-12-ol, 3,4,4a,5,16a,17,18,19-octahydro-21,22,26-trimethoxy-4,17-dimethyl-, (4as,16ar)-
chebi:3063 ,
CHEMBL504323 ,
unii-v5km4xj0wm
2-27-00-00891 (beilstein handbook reference)
v5km4xj0wm ,
S9141
NCGC00017375-02
AKOS015896768
berbamine, (+)-
berbamine [who-dd]
berbamine [mi]
SCHEMBL19039
SR-05000002322-2
sr-05000002322
Q4891024
tert-butyl1,3-benzodioxol-4-ylcarbamate
NCGC00017375-03
DTXSID40963943
HY-N0714
CS-0009732
CCG-270219
MS-30684
AC-20191
20,21,25-trimethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaen-9-ol
CHEBI:182116
6,6',7-trimethoxy-2,2'-dimethylberbaman-12-ol
nsc-105131
478-61-5
berbamine
NCI60_000125
gnf-pf-1034 ,
mmv007474
STK801360
AKOS005612992
CHEMBL1198334
FT-0622872
SCHEMBL19041
Q-100513
mfcd00067632
AC-1313
BCP29709
d-berbamine pound>>6,6',7-trimethoxy-2,2'-dimethyl-berbaman-12-ol
nsc-766769
nsc766769

Research Excerpts

Overview

Berbamine (BBM) is a natural bisbenzylisoquinoline alkaloid extracted from Berberis amurensis. It possesses multiple pharmacological activity including anticancer. Berbamine exerts an effect on inhibiting cancer cell proliferation.

ExcerptReferenceRelevance
"Berbamine is a nonbasic quaternary benzylisoquinoline plant alkaloid that has been widely used in the clinic to treat leukopenia in China."( The Dibenzyl Isoquinoline Alkaloid Berbamine Ameliorates Osteoporosis by Inhibiting Bone Resorption.
Ghalandari, B; Ghorbani, F; Irani, S; Mohamadali, M; Qian, Z; Sang, W; Yi, C; Yu, B; Zhang, C; Zhong, Z, 2022
)
1.72
"Berbamine (BBM) is a natural bisbenzylisoquinoline alkaloid extracted from Berberis amurensis which possesses multiple pharmacological activity including anticancer."( Berbamine dihydrochloride suppresses the progression of colorectal cancer via RTKs/Akt axis.
Chen, N; Liang, D; Liu, L; Lv, R; Tang, J; Zhao, M; Zheng, Q, 2023
)
3.07
"Berbamine is an alkaloid extracted from the Chinese herb berberis, which exerts an effect on inhibiting cancer cell proliferation."( Berbamine Inhibits the Biological Activities of Prostate Cancer Cells by Modulating the ROS/NF-κB Axis.
Guo, Y; Jia, X; Jiang, Y; Wang, X; Zhao, W, 2023
)
3.07
"Berbamine is a plant-derived alkaloid with amazing and wide diversity of pharmacological properties which range from antimicrobial and anticancer. "( Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signalling pathway.
Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Liu, G; Liu, J; Mou, L; Ye, L; Zang, N; Zhou, B,
)
3.02
"Berbamine is a bisbenzylisoquinoline alkaloid extracted from Berberis poiretii of Berberis of Berberidaceae. "( Effect of berbamine on invasion and metastasis of human liver cancer SMMC-7721 cells and its possible mechanism.
Cao, JB; Cao, Y; Liu, LL; Yan, JD; Yu, BB, 2022
)
2.57
"Berbamine (BBM) is a natural compound extracted from traditional Chinese medicine that is widely used for treatment of a variety of diseases without any obvious side effects."( A novel autophagy inhibitor berbamine blocks SNARE-mediated autophagosome-lysosome fusion through upregulation of BNIP3.
Deng, Q; Fu, R; Gao, N; Hu, J; Hu, X; Jiang, X; Li, L; Li, Y; Liu, Y; Luo, Q; Yang, C; Zhang, H; Zhang, Y, 2018
)
1.5
"Berbamine is a natural compound from the plant Berberis amurensis, which is used in Chinese traditional medicine."( Berbamine suppresses cell proliferation and promotes apoptosis in ovarian cancer partially via the inhibition of Wnt/β-catenin signaling.
Chang, Y; Jiao, Y; Ren, Y; Shi, C; Shi, X; Song, X; Zhang, H, 2018
)
2.64
"Berbamine (BBM) is a natural compound derived from the Berberis amurensis plants."( A novel synthetic derivative of the natural product berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associated with activation of JNK/AP-1 signaling.
Horne, DA; Jove, R; Liu, L; Nam, S; Tian, Y; Yang, F; Zhao, R, 2013
)
1.36
"Berbamine (BBM) is a natural compound derived from the Berberis amurensis plant, and along with its derivatives, has been shown to exhibit antitumor activity in several cancers."( A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling.
Brown, CE; Hickey, RJ; Horne, DA; Jove, R; Ma, Y; Malkas, LH; Nam, S; Starr, R; Xie, J; Yang, F; Zhao, R, 2014
)
1.56
"Berbamine (BBM) is a bisbenzylisoquinoline alkaloid isolated from herbal medicine Berberis amurensis. "( In vitro and in vivo metabolic activation of berbamine to quinone methide intermediate.
Li, H; Peng, Y; Sun, Y; Yao, T; Zheng, J, 2017
)
2.16
"Berbamine (BM) is an herbal compound derived from Berberis vulgaris L commonly used in traditional Chinese medicine. "( Novel immunomodulatory properties of berbamine through selective down-regulation of STAT4 and action of IFN-gamma in experimental autoimmune encephalomyelitis.
Guo, TB; Liu, A; Lu, L; Qiu, J; Ren, Y; Yang, Y; Zhang, JZ, 2008
)
2.06

Effects

Berbamine (BER) has been reported to exert anti-proliferative effects against a series of cancers. Berbamine (BBM) has the potency to act as a therapeutic in multiple cancers and cancer metastasis.

ExcerptReferenceRelevance
"Berbamine (BBM) has the potency to act as a therapeutic in multiple cancers and cancer metastasis."( Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo.
Kumar Sahoo, S; Parhi, P; Suklabaidya, S, 2017
)
1.42
"Berbamine (BER) has been initially reported to exert anti-proliferative effects against a series of cancers."( In vitro and in vivo antitumor evaluation of berbamine for lung cancer treatment.
Chen, C; Hou, ZB; Huang, XE; Lu, KJ; Wu, XL; Yin, HT, 2014
)
1.38
"Berbamine (BBM) has been reported with antitumor activities. "( Berbamine inhibited the growth of prostate cancer cells in vivo and in vitro via triggering intrinsic pathway of apoptosis.
Chen, J; Jin, XB; Lv, JJ; Su, ZH; Wang, LY; Wang, MW; Zhang, HY; Zhao, Y, 2016
)
3.32

Actions

Berbamine could activate Caspase-3 to induce human leukemia K562/Adr cell apoptosis, and by reducing mdr-1 gene expression to reverse its multidrug resistance. Berbamine could inhibit the growth of leukemia cell line NB4.

ExcerptReferenceRelevance
"Berbamine could inhibit human leukemia K562/Adr cell growth in dose-dependent manner, it could also induce cell apoptosis, increase the protein expression of Caspase-3 and the drug excretion capacity of cells, reduce the mRNA and protein expression levels of mdr-1 gene."( [Study on effect of berbamine on multidrug resistance leukemia K562/Adr cells].
Dong, QH; He, L; Lu, Q; Xu, RZ; Zheng, S, 2004
)
2.09
"Berbamine could activate Caspase-3 to induce human leukemia K562/Adr cell apoptosis, and by reducing mdr-1 gene expression to reverse its multidrug resistance."( [Study on effect of berbamine on multidrug resistance leukemia K562/Adr cells].
Dong, QH; He, L; Lu, Q; Xu, RZ; Zheng, S, 2004
)
2.09
"Berbamine could inhibit the growth of leukemia cell line NB4. "( [Effects of berbamine on growth of leukemia cell line NB4 and its mechanism].
He, ZW; Wu, D; Xu, RZ; Zhao, XY, 2006
)
2.16

Treatment

Berbamine treatment led to increased expression of A20, down-regulation of IKKalpha, p-IkappaBalpha, and followed by inhibition of p65 nuclear localization. Berbamine pretreatment from 10 to 100nmol/L concentration-dependently improved post-ischemic myocardial function.

ExcerptReferenceRelevance
"Berbamine-treated K562-r cells also exhibited down-regulated expression of the anti-apoptotic proteins Bcl-2 and Bcl-x(L), up-regulated expression of the apoptotic proteins Bax and cytoplasmic cyt C, and stimulated proteolytic cleavage of PARP."( Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.
Liang, Y; Wei, YL; Xu, L; Xu, XH; Zhao, XY, 2009
)
2.52
"Berbamine treatment decreased the cell growth in a dose-dependent manner with an IC(50) value of 34.5 +/- 0.5 microM."( Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice.
Dong, Q; Dong, QH; Lv, QH; Wang, GY; Xu, RZ, 2009
)
2.52
"Berbamine treatment led to increased expression of A20, down-regulation of IKKalpha, p-IkappaBalpha, and followed by inhibition of p65 nuclear localization."( Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells.
Liang, Y; Xu, RZ; Zhang, L; Zhao, XY, 2009
)
2.52
"Berbamine pretreatment from 10 to 100nmol/L concentration-dependently improved post-ischemic myocardial function. "( Berbamine protects the heart from ischemia/reperfusion injury by maintaining cytosolic Ca(2+) homeostasis and preventing calpain activation.
Gao, L; Yang, HT; Zhang, CM; Zheng, YJ, 2012
)
3.26
"Pretreatment of berbamine protects the heart from ischemia/reperfusion (I/R) injury. "( Berbamine postconditioning protects the heart from ischemia/reperfusion injury through modulation of autophagy.
Gao, L; Gu, S; Jiang, Y; Li, X; Liu, S; Tan, J; Yang, HT; Zhang, C; Zheng, Y, 2017
)
2.24

Pharmacokinetics

ExcerptReferenceRelevance
" The validated method was successfully applied to the preclinical pharmacokinetic studies of BBM in rats."( A rapid and sensitive LC-MS/MS assay for the determination of berbamine in rat plasma with application to preclinical pharmacokinetic study.
Jia, Y; Kong, L; Liu, Q; Wang, J; Yang, L, 2013
)
0.63
" The purpose of this study is to develop an UPLC-MS/MS method to quantify TET and its major metabolite and apply the method in a single dose human pharmacokinetic study."( An UPLC-MS/MS method for quantifying tetrandrine and its metabolite berbamine in human blood: Application to a human pharmacokinetic study.
Gao, S; Hu, M; Hu, P; Yang, G; Zhang, C; Zhu, M, 2017
)
0.69

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
" The relatively improved oral bioavailability and better antitumour efficacy indicated that the dual-drug CD/CS NPs developed in our study possessed significant advantages and might be a promising strategy for the development of drug, delivery systems for cancer chemotherapy."( Co-Delivery of Docetaxel and Berbamine by Chitosan/Sulfobutylether-β-Cyclodextrin Nanoparticles for Enhancing Bioavailability and Anticancer Activities.
Bu, X; Dou, L; Fang, L; Shen, Q; Wu, J, 2015
)
0.71
" However, the major limitation of the compound includes poor bioavailability at the tumor site due to short plasma half-life."( Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo.
Kumar Sahoo, S; Parhi, P; Suklabaidya, S, 2017
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
bisbenzylisoquinoline alkaloidA type of benzylisoquinoline alkaloid whose structures are built up of two benzylisoquinoline units linked by ether bridges. Various structural patterns resulting from additional bridging between the two units by direct carbon-carbon bridging or by methylenedioxy groups are common.
phenylpropanoidAny organic aromatic compound with a structure based on a phenylpropane skeleton. The class includes naturally occurring phenylpropanoid esters, flavonoids, anthocyanins, coumarins and many small phenolic molecules as well as their semi-synthetic and synthetic analogues. Phenylpropanoids are also precursors of lignin.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
TDP1 proteinHomo sapiens (human)Potency9.44110.000811.382244.6684AID686979
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency3.16230.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency15.84890.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.84890.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseHomo sapiens (human)IC50 (µMol)100.00000.00001.559910.0000AID1537270
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Ki0.19000.00010.579710.0000AID397127
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki0.19000.00011.48339.1400AID397127
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)Ki0.19000.00010.68688.2600AID397127
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)Ki0.19000.00010.66618.2600AID397127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)7.87000.00022.45859.9600AID1804171
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki0.19000.00010.58908.2600AID397127
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)100.00000.00000.933210.0000AID1537269
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)22.00000.00021.557410.0000AID397126
Prolyl endopeptidaseHomo sapiens (human)IC50 (µMol)200.00000.00111.98969.7500AID1537274
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)IC50 (µMol)22.00000.23002.510510.0000AID397126
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
proteolysisProlyl endopeptidaseHomo sapiens (human)
regulation of smooth muscle cell apoptotic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
cGMP catabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
regulation of smooth muscle cell proliferationCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (43)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
serine-type endopeptidase activityProlyl endopeptidaseHomo sapiens (human)
protein bindingProlyl endopeptidaseHomo sapiens (human)
serine-type peptidase activityProlyl endopeptidaseHomo sapiens (human)
oligopeptidase activityProlyl endopeptidaseHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nucleusProlyl endopeptidaseHomo sapiens (human)
cytoplasmProlyl endopeptidaseHomo sapiens (human)
cytosolProlyl endopeptidaseHomo sapiens (human)
membraneProlyl endopeptidaseHomo sapiens (human)
cytosolProlyl endopeptidaseHomo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (42)

Assay IDTitleYearJournalArticle
AID1537277Permeability of the compound after 2.45 hrs by PAMPA2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID377945Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID674576Induction of rat C/EBPalpha expression transfected in human U937 cells at 50 uM after 24 hrs by luciferase reporter gene assay relative to ATRA2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID397126Inhibition of calmodulin-dependent phosphodiesterase
AID429191Cell cycle arrest in human imatinib-resistant K562 cells assessed as accumulation at G2/M phase at 2 ug/ml after 48 hrs by flow cytometry2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Berbamine derivatives: a novel class of compounds for anti-leukemia activity.
AID377944Cytotoxicity against human KB cells after 72 hrs by SRB assay1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID397127Displacement of [3H]QNB from rat brain muscarinic receptor
AID1854076Antiproliferative activity against human KM3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID377947Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs1999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID397139Inhibition of calmodulin-stimulated Ca2+/Mg2+ ATPase activity in human erythrocyte membrane
AID429192Induction of apoptosis in human imatinib-resistant K562 cells expressing p210Bcr/Abl at 1 ug/ml after 48 hrs by flow cytometry2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Berbamine derivatives: a novel class of compounds for anti-leukemia activity.
AID1663397Inhibition of P-glycoprotein-mediated Rhodamine-123 efflux in human MOLT4/DNR cells assessed as inhibition of P-glycoprotein efflux function at 10 uM incubated for 1 hr by flow cytometry2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
AID674579Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID1537274Inhibition of POP (unknown origin) using (Z)-Gly-Pro-p-nitroanilide as substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by spectrophotometric method2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID674583Cytotoxicity against human U937 cells assessed as cell growth at 50 uM after 24 hrs by alamar blue assay2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID429101Cytotoxicity against human imatinib-resistant K562 leukemia cells expressing p210Bcr/Abl and MDR1 at 48 hrs by MTT assay2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Berbamine derivatives: a novel class of compounds for anti-leukemia activity.
AID1854074Antiproliferative activity against human KM3 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID429103Inhibition of NF-kappaB translocation from cytoplasm to nucleus in human imatinib-resistant K562 leukemia cells expressing p210Bcr/Ab assessed as disappearance of NF-kappaB p65/relA subunit nuclear level at 0.5 ug/ml after 24 hrs by Western blot analysis2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Berbamine derivatives: a novel class of compounds for anti-leukemia activity.
AID1854072Antiproliferative activity against imatinib resistant human K562 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID1537270Inhibition of human BuChE using butyrylthiocholine iodide as substrate measured for 1 min by Ellman's method2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1537271Selectivity index, ratio of IC50 for human BuChE to IC50 for human AChE2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1663396Inhibition of P-glycoprotein-mediated Rhodamine-123 efflux in human MOLT4/DNR cells assessed as inhibition of P-glycoprotein efflux function at 1 uM incubated for 1 hr by flow cytometry2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
AID1537276Inhibition of GSK3B (unknown origin) at 10 uM relative to control2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1854073Antiproliferative activity against imatinib resistant human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID377948Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum W21999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID429102Inhibition of NF-kappaB translocation from cytoplasm to nucleus in human imatinib-resistant K562 leukemia cells expressing p210Bcr/Ab assessed as disappearance of NF-kappaB p65/relA subunit nuclear level at 8 ug/ml after 24 hrs by Western blot analysis2009European journal of medicinal chemistry, Aug, Volume: 44, Issue:8
Berbamine derivatives: a novel class of compounds for anti-leukemia activity.
AID377946Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum D61999Journal of natural products, Jan, Volume: 62, Issue:1
Antiplasmodial and cytotoxic activity of natural bisbenzylisoquinoline alkaloids.
AID1663395Inhibition of P-glycoprotein-mediated Rhodamine-123 efflux in human MOLT4/DNR cells assessed as inhibition of P-glycoprotein efflux function at 0.3 uM incubated for 1 hr by flow cytometry2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Bisbenzylisoquinoline alkaloids and P-glycoprotein function: A structure activity relationship study.
AID397128Inhibition of formyl-methionyl-leucyl-phenylalanine induced superoxide generation in PMNC
AID1854077Cytotoxicity against human Hematopoietic stem cell assessed as cell growth inhibition measured after 48 hrs by MTT assay2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID1537269Inhibition of human AChE using acetylthiocholine iodide as substrate measured for 1 min by Ellman's method2019Journal of natural products, 02-22, Volume: 82, Issue:2
Isoquinoline Alkaloids from Berberis vulgaris as Potential Lead Compounds for the Treatment of Alzheimer's Disease.
AID1854075Antiproliferative activity against human KM3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay2022European journal of medicinal chemistry, Aug-05, Volume: 238The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
AID1743206Cytotoxicity against human HepG2 cells overexpressing EGFP-CYP3A4 assessed as reduction in cell viability at 15 uM measured after 24 hrs by propidium iodide staining based flow cytometry2020European journal of medicinal chemistry, Dec-01, Volume: 207Synthesis, biological evaluation and toxicity of novel tetrandrine analogues.
AID674572Induction of rat C/EBPalpha expression transfected in human U937 cells after 24 hrs by luciferase reporter gene assay relative to ATRA2012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Discovery and preliminary SAR of bisbenzylisoquinoline alkaloids as inducers of C/EBPα.
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
AID1673545Inhibition of recombinant Trypanosoma brucei rhodesain expressed in Pichia pastoris at 5 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition and measured at 12 sec interval for 5 mins by fluorimetric analysis relative to2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID1673543Inhibition of recombinant Trypanosoma cruzi cruzain at 5 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition and measured at 12 sec interval for 5 mins by fluorimetric analysis relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID1673542Inhibition of recombinant Trypanosoma cruzi cruzain at 5 uM using Z-FR-AMC as substrate and measured at 12 sec interval for 5 mins without preincubation by fluorimetric analysis relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
AID1673544Inhibition of recombinant Trypanosoma brucei rhodesain expressed in Pichia pastoris at 5 uM using Z-FR-AMC as substrate and measured at 12 sec interval for 5 mins without preincubation by fluorimetric analysis relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Discovery and characterization of trypanocidal cysteine protease inhibitors from the 'malaria box'.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (151)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (9.27)18.7374
1990's35 (23.18)18.2507
2000's29 (19.21)29.6817
2010's39 (25.83)24.3611
2020's34 (22.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.27 (24.57)
Research Supply Index5.00 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index83.48 (26.88)
Search Engine Supply Index3.99 (0.95)

This Compound (32.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (0.68%)5.53%
Reviews3 (27.27%)6.00%
Reviews3 (2.04%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other8 (72.73%)84.16%
Other143 (97.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]